SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0001140361-16-061144
Filing Date
2016-04-14
Accepted
2016-04-14 17:14:10
Documents
4
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 NOVARTIS BIOVENTURES LTD. SC 13G 4-6-2016 (AEGLEA BIOTHERAPEUTICS, INC) formsc13g.htm SC 13G 83655
2 EXHIBIT 99.1 ex99_1.htm EX-99.1 22483
3 EXHIBIT 99.2 ex99_2.htm EX-99.2 6186
4 EXHIBIT 99.3 ex99_3.htm EX-99.3 7778
  Complete submission text file 0001140361-16-061144.txt   121745
Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Filed by) CIK: 0001297709 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Subject) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-89456 | Film No.: 161572483
SIC: 2834 Pharmaceutical Preparations